CorInsights - Model MRI -Advanced Reporting Tool
At ADMdx, we’re applying advances in image measurement and analysis to support earlier, more accurate identification of brain disorders including Alzheimer’s disease and other dementias. CorInsights MRI, our first FDA 510k cleared product, is powered by ADMdx technology. This advanced reporting tool uses readily available MRI brain scans to support medical professionals in providing a new standard of care.
- Alzheimer’s disease progression from amyloid negative controls through amyloid and tau positive AD dementia
- Atypical Alzheimer’s disease variants including Posterior Cortical Atrophy, amyloid positive Corticobasal Syndrome, and amyloid positive Logopenic Progressive Aphasia, and Early Onset Alzheimer’s Disease
- Frontotemporal dementia variants including behavioral, semantic dementia, primary progressive aphasia, and nonfluent progressive aphasia
- Traumatic brain injury
- Parkinson’s disease
- White matter / cerebrovascular disease
- Down Syndrome
ADMdx provides a full spectrum of imaging CRO services for CNS imaging trials using PET and MRI biomarkers, including:
- Protocol input, charter and technical manual development
- Imaging site identification and qualification
- Central data receipt and quality control
- Radiology reads
- Advanced image processing and analysis
- Reporting
- Data management and archival
We support clinical trial success by combining key elements of CLARITY, QUALITY, PARTNER FOCUS, and INSIGHT.
Using our reference database and multivariate image classification, we address critical questions to support trial success:
- Patient inclusion based upon:
- Disease patterns
- Pathology
- Patient stratification for analysis, by predicting:
- Rates of clinical decline
- Pathology accumulation rates
- Detection of treatment effect
- Treatment responder characteristics
